{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:21:06Z","timestamp":1790014866257,"version":"4.0.1"},"reference-count":173,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Despite significant advancements in ocular drug delivery, challenges persist in treating posterior segment diseases like macular edema (ME) and age-related macular degeneration (AMD). Suprachoroidal (SC) injections are a promising new method for targeted drug delivery to the posterior segment of the eye, providing direct access to the choroid and retina while minimizing systemic exposure and side effects. This review examines the anatomical and physiological foundations of the SC space; evaluates delivery devices such as microcatheters, hypodermic needles, and microneedles; and discusses pharmacokinetic principles. Additionally, advancements in gene delivery through SC injections are explored, emphasizing their potential to transform ocular disease management. This review also highlights clinical applications in treating macular edema, diabetic macular edema, age-related macular degeneration, choroidal melanoma, and glaucoma. Overall, SC injections are emerging as a promising novel route for administering ophthalmic treatments, with high bioavailability, reduced systemic exposure, and favorable safety profiles. Key therapeutic agents such as triamcinolone acetonide, dexamethasone, AAV-based gene therapy, and axitinib have shown promise. The field of suprachoroidal injection is progressing rapidly, and this review article, while attempting to encapsulate most of the published preclinical and clinical studies, mainly focuses on those that are published within 2023 and 2024.<\/jats:p>","DOI":"10.3390\/ph17081007","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:08:34Z","timestamp":1722359314000},"page":"1007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["What\u2019s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-6900","authenticated-orcid":false,"given":"Kevin Y.","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Gao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Giunta","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-359X","authenticated-orcid":false,"given":"Simon D.","family":"Tran","sequence":"additional","affiliation":[{"name":"Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/jps.23127","article-title":"MRI Study of Subconjunctival and Intravitreal Injections","volume":"101","author":"Li","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse Events and Complications Associated with Intravitreal Injection of Anti-VEGF Agents: A Review of Literature","volume":"27","author":"Nguyen","year":"2013","journal-title":"Eye"},{"key":"ref_3","unstructured":"Tasman, W., and Jaeger, E.A. (2007). Duane\u2019s Ophthalmology, Lippincott Williams & Wilkins."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Vurgese, S., Panda-Jonas, S., and Jonas, J.B. (2012). Scleral Thickness in Human Eyes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029692"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.exer.2009.11.001","article-title":"Dimensions of the Human Sclera: Thickness Measurement and Regional Changes with Axial Length","volume":"90","author":"Norman","year":"2010","journal-title":"Exp. Eye Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.ijg.0000212220.42675.c5","article-title":"Central Corneal Thickness Is Not Related to Anterior Scleral Thickness or Axial Length","volume":"15","author":"Oliveira","year":"2006","journal-title":"J. Glaucoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.exer.2014.02.020","article-title":"Mechanical Properties of Murine and Porcine Ocular Tissues in Compression","volume":"121","author":"Worthington","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bjophthalmol-2013-303904","article-title":"Direct Comparison of Spectral-Domain and Swept-Source OCT in the Measurement of Choroidal Thickness in Normal Eyes","volume":"98","author":"Copete","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2008.05.032","article-title":"Enhanced Depth Imaging Spectral-Domain Optical Coherence Tomography","volume":"146","author":"Spaide","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.35119\/asjoo.v16i4.434","article-title":"Optimized Imaging of the Suprachoroidal Space with Swept-Source OCT","volume":"16","author":"Hanhart","year":"2019","journal-title":"Asian J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the Suprachoroidal Space: A Novel Drug Delivery Methodology to the Posterior Segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of Pars Plana Intravitreal Injections versus Microcannula Suprachoroidal Injections of Bevacizumab in a Porcine Model","volume":"52","author":"Olsen","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2147\/OPTH.S57217","article-title":"A Review of the iStent\u00ae Trabecular Micro-Bypass Stent: Safety and Efficacy","volume":"9","author":"Wellik","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_14","first-page":"875","article-title":"Prospective Unmasked Randomized Evaluation of the iStent Inject\u00ae versus Two Ocular Hypotensive Agents in Patients with Primary Open-Angle Glaucoma","volume":"8","author":"Fea","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-Vectored Suprachoroidal Gene Transfer Produces Widespread Ocular Transgene Expression","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eaba1606","DOI":"10.1126\/sciadv.aba1606","article-title":"Suprachoroidal Gene Transfer with Nonviral Nanoparticles","volume":"6","author":"Shen","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9394(99)80096-8","article-title":"Human Sclera: Thickness and Surface Area","volume":"125","author":"Olsen","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2015.02.021","article-title":"Safety and Pharmacodynamics of Suprachoroidal Injection of Triamcinolone Acetonide as a Controlled Ocular Drug Release Model","volume":"203","author":"Chen","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow Microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted Administration into the Suprachoroidal Space Using a Microneedle for Drug Delivery to the Posterior Segment of the Eye","volume":"53","author":"Patel","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wan, C.-R., Muya, L., Kansara, V., and Ciulla, T.A. (2021). Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020288"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chiang, B., Jang, K., Goldberg, J., and Myung, D. (2024). Design and Ex Vivo Development of a Suprachoroidal Spacer Implant to Treat Glaucoma, Springer.","DOI":"10.21203\/rs.3.rs-3895533\/v1"},{"key":"ref_23","unstructured":"Everads Therapy (2023, December 31). Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients with DME, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06314217."},{"key":"ref_24","first-page":"2623","article-title":"Laboratory-Made Needle for Suprachoroidal Injections in Living Animals and Human Eye Bank Eyes","volume":"64","author":"Katz","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular Drug Delivery: A Comprehensive Review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3928\/23258160-20170928-01","article-title":"Treatment Burden in Neovascular AMD:Visual Acuity Outcomes Are Associated with Anti-VEGF Injection Frequency","volume":"48","author":"Hussain","year":"2017","journal-title":"Ophthalmic. Surg. Lasers Imaging Retin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther. Off J. Assoc. Ocul. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Peden, M.C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S.L., Levine, M., Hauswirth, W.W., Ratnakaram, R., and Dawson, W. (2011). Ab-Externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017140"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of Suprachoroidal Drug Delivery: From Benchtop to Clinical Investigation in Ocular Therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jval.2022.07.008","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated with Uveitis in the United States: A Cost-Effectiveness Analysis","volume":"25","author":"Bhattacharyya","year":"2022","journal-title":"Value Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.jval.2022.04.358","article-title":"EE105 Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal Use, for the Treatment of Macular Edema Associated with Uveitis in the United States: A Budget Impact Analysis","volume":"25","author":"Bhattacharyya","year":"2022","journal-title":"Value Health"},{"key":"ref_32","unstructured":"(2024, June 21). DailyMed\u2014XIPERE\u2014Triamcinolone Acetonide Injection, Suspension, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=ea6ad429-967f-4f75-a33d-e06f849bee80."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/IAE.0000000000004087","article-title":"Suprachoroidal Space Injection Technique: Expert Panel Guidance","volume":"44","author":"Wykoff","year":"2024","journal-title":"Retina"},{"key":"ref_34","first-page":"1209","article-title":"Safety of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders","volume":"62","author":"Sharma","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","unstructured":"Joszt, L. (2024, May 28). Xipere for Macular Edema Associated with Uveitis Launches in United States. Available online: https:\/\/www.ajmc.com\/view\/xipere-for-macular-edema-associated-with-uveitis-launches-in-united-states."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tyagi, P., Kadam, R.S., and Kompella, U.B. (2012). Comparison of Suprachoroidal Drug Delivery with Subconjunctival and Intravitreal Routes Using Noninvasive Fluorophotometry. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048188"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/IAE.0b013e3181f049a8","article-title":"Diabetic Retinopathy Clinical Research Network Ocular Side Effects Associated with Peribulbar Injections of Triamcinolone Acetonide for Diabetic Macular Edema","volume":"31","author":"Chew","year":"2011","journal-title":"Retina"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1877912311202020082","article-title":"Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery","volume":"2","author":"Cholkar","year":"2012","journal-title":"Recent Pat. Nanomed."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2108360","DOI":"10.1002\/adma.202108360","article-title":"Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease","volume":"34","author":"Zhao","year":"2022","journal-title":"Adv. Mater."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.2147\/IJN.S329831","article-title":"Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective","volume":"16","author":"Zhang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cis.2018.11.008","article-title":"Pharmaceutical Applications of Chitosan","volume":"263","author":"Shariatinia","year":"2019","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The Use of Mucoadhesive Polymers in Ocular Drug Delivery","volume":"57","author":"Ludwig","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"118217","DOI":"10.1016\/j.carbpol.2021.118217","article-title":"Chitosan Coated Nanoparticles for Efficient Delivery of Bevacizumab in the Posterior Ocular Tissues via Subconjunctival Administration","volume":"267","author":"Pandit","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lyu, Q., Peng, L., Hong, X., Fan, T., Li, J., Cui, Y., Zhang, H., and Zhao, J. (2021). Smart Nano-Micro Platforms for Ophthalmological Applications: The State-of-the-Art and Future Perspectives. Biomaterials, 270.","DOI":"10.1016\/j.biomaterials.2021.120682"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.biopha.2018.08.092","article-title":"Effect of Nanoencapsulation Using Poly (Lactide-Co-Glycolide) (PLGA) on Anti-Angiogenic Activity of Bevacizumab for Ocular Angiogenesis Therapy","volume":"107","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.04.012","article-title":"Highly Bioactive, Bevacizumab-Loaded, Sustained-Release PLGA\/PCADK Microspheres for Intravitreal Therapy in Ocular Diseases","volume":"563","author":"Liu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Prieto, E., Cardiel, M.J., Vispe, E., Idoipe, M., Garcia-Martin, E., Fraile, J.M., Polo, V., Mayoral, J.A., Pablo, L.E., and Rodrigo, M.J. (2020). Dexamethasone Delivery to the Ocular Posterior Segment by Sustained-Release Laponite Formulation. Biomed. Mater., 15.","DOI":"10.1088\/1748-605X\/aba445"},{"key":"ref_49","first-page":"1705","article-title":"Solid Lipid Nanoparticles for the Delivery of a Sustained-Release Small Molecule Antioxidant for RPE Protection in Dry AMD","volume":"60","author":"Arta","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tzameret, A., Ketter-Katz, H., Edelshtain, V., Sher, I., Corem-Salkmon, E., Levy, I., Last, D., Guez, D., Mardor, Y., and Margel, S. (2019). In Vivo MRI Assessment of Bioactive Magnetic Iron Oxide\/Human Serum Albumin Nanoparticle Delivery into the Posterior Segment of the Eye in a Rat Model of Retinal Degeneration. J. Nanobiotechnol., 17.","DOI":"10.1186\/s12951-018-0438-y"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.exer.2010.09.003","article-title":"Gold Nanoparticles Downregulate VEGF-and IL-1\u03b2-Induced Cell Proliferation through Src Kinase in Retinal Pigment Epithelial Cells","volume":"91","author":"Karthikeyan","year":"2010","journal-title":"Exp. Eye Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1167\/iovs.12-10743","article-title":"Effects of Gold Nanoparticles on Endotoxin-Induced Uveitis in Rats","volume":"53","author":"Pereira","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"(Chezy) Doxil\u00ae\u2014The First FDA-Approved Nano-Drug: Lessons Learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_54","first-page":"624","article-title":"Photodynamic Therapy with Verteporfin (Visudyne): Impact on Ophthalmology and Visual Sciences","volume":"41","author":"Bressler","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_55","first-page":"416","article-title":"Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery","volume":"34","author":"Hsiao","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther. Off J. Assoc. Ocul. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/10717544.2019.1571122","article-title":"A More Efficient Ocular Delivery System of Triamcinolone Acetonide as Eye Drop to the Posterior Segment of the Eye","volume":"26","author":"Li","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"117216","DOI":"10.1016\/j.carbpol.2020.117216","article-title":"Hydrogel Eye Drops as a Non-Invasive Drug Carrier for Topical Enhanced Adalimumab Permeation and Highly Efficient Uveitis Treatment","volume":"253","author":"Chen","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2109173","DOI":"10.1002\/adfm.202109173","article-title":"Multifunctional Supramolecular Filament Hydrogel Boosts Anti-Inflammatory Efficacy In Vitro and In Vivo","volume":"32","author":"Deng","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hackett, S.F., Fu, J., Kim, Y.C., Tsujinaka, H., Shen, J., Lima, E., Silva, R., Khan, M., Hafiz, Z., and Wang, T. (2020). Sustained Delivery of Acriflavine from the Suprachoroidal Space Provides Long Term Suppression of Choroidal Neovascularization. Biomaterials, 243.","DOI":"10.1016\/j.biomaterials.2020.119935"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2018.1389886","article-title":"Gene Therapy for Inherited Retinal and Optic Nerve Degenerations","volume":"18","author":"Moore","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jconrel.2018.07.013","article-title":"Non-Viral Ocular Gene Therapy, pEYS606, for the Treatment of Non-Infectious Uveitis: Preclinical Evaluation of the Medicinal Product","volume":"285","author":"Touchard","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Shen, W., Liu, S., and Ou, L. (2022). rAAV Immunogenicity, Toxicity, and Durability in 255 Clinical Trials: A Meta-Analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1001263"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/fvl.11.6","article-title":"Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors","volume":"6","author":"Gregory","year":"2011","journal-title":"Future Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral Vector Vaccine Platforms in the SARS-CoV-2 Pandemic","volume":"6","author":"Lorincz","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jgm.845","article-title":"Stable and Efficient Intraocular Gene Transfer Using Pseudotyped EIAV Lentiviral Vectors","volume":"8","author":"Balaggan","year":"2006","journal-title":"J. Gene Med."},{"key":"ref_67","first-page":"317","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_69","unstructured":"AbbVie (2023, December 31). RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants with Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04514653."},{"key":"ref_70","first-page":"1497","article-title":"Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATETM Study","volume":"63","author":"Khanani","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_71","unstructured":"AbbVie (2023, December 31). RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants with Diabetic Retinopathy (DR) without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04567550."},{"key":"ref_72","unstructured":"REGENXBIO (2024, May 30). REGENXBIO Presents Positive Interim Data from Phase II ALTITUDETM Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery. Available online: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-presents-positive-interim-data-phase-ii-altitudetm\/."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41467-024-48221-4","article-title":"An Adeno-Associated Virus Variant Enabling Efficient Ocular-Directed Gene Delivery across Species","volume":"15","author":"Luo","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/hum.2013.009","article-title":"Vesicular Stomatitis Virus Glycoprotein- and Venezuelan Equine Encephalitis Virus-Derived Glycoprotein-Pseudotyped Lentivirus Vectors Differentially Transduce Corneal Endothelium, Trabecular Meshwork, and Human Photoreceptors","volume":"25","author":"Lipinski","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/jgm.788","article-title":"Retinal Cell Type Expression Specificity of HIV-1-Derived Gene Transfer Vectors upon Subretinal Injection in the Adult Rat: Influence of Pseudotyping and Promoter","volume":"7","author":"Bemelmans","year":"2005","journal-title":"J. Gene Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.gt.3302485","article-title":"Lentiviral Vector-Mediated Gene Transfer in Adult Mouse Photoreceptors Is Impaired by the Presence of a Physical Barrier","volume":"12","author":"Kostic","year":"2005","journal-title":"Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.gt.3302897","article-title":"Lentiviral Gene Replacement Therapy of Retinas in a Mouse Model for Usher Syndrome Type 1B","volume":"14","author":"Hashimoto","year":"2007","journal-title":"Gene Ther."},{"key":"ref_78","unstructured":"Shanghai BDgene Co., Ltd. (2024, June 01). VEGFA-Targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT05099094."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41587-019-0402-x","article-title":"Emerging Patent Landscape for Non-Viral Vectors Used for Gene Therapy","volume":"38","author":"Pereira","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.adgen.2014.10.003","article-title":"Electroporation-Mediated Gene Delivery","volume":"89","author":"Young","year":"2015","journal-title":"Adv. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1208\/s12248-009-9143-y","article-title":"Nonviral Gene Delivery: Principle, Limitations, and Recent Progress","volume":"11","author":"Gao","year":"2009","journal-title":"AAPS J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"949","DOI":"10.18609\/cgti.2019.104","article-title":"Viral Vector Manufacturing: How to Address Current and Future Demands?","volume":"5","author":"Masri","year":"2019","journal-title":"Cell Gene Ther. Insights"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Sainz-Ramos, M., Gallego, I., Villate-Beitia, I., Zarate, J., Maldonado, I., Puras, G., and Pedraz, J.L. (2021). How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147545"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jconrel.2015.10.007","article-title":"Non-Viral Therapeutic Approaches to Ocular Diseases: An Overview and Future Directions","volume":"219","author":"Zulliger","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rai, R., Alwani, S., and Badea, I. (2019). Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications. Polymers, 11.","DOI":"10.3390\/polym11040745"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/978-1-4614-3209-8_88","article-title":"Episomal Maintenance of S\/MAR-Containing Non-Viral Vectors for RPE-Based Diseases","volume":"801","author":"Koirala","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_87","first-page":"e326497","article-title":"Liposomes for Use in Gene Delivery","volume":"2011","author":"Balazs","year":"2010","journal-title":"J. Drug Deliv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtn.2017.02.005","article-title":"Targeted Multifunctional Lipid ECO Plasmid DNA Nanoparticles as Efficient Non-Viral Gene Therapy for Leber\u2019s Congenital Amaurosis","volume":"7","author":"Sun","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_89","first-page":"2909","article-title":"Suprachoroidally Delivered Non-Viral DNA Nanoparticles Transfect Chorioretinal Cells in Non-Human Primates and Rabbits","volume":"60","author":"Kansara","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.9.13.21","article-title":"Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium\/Choroid in Rabbits","volume":"9","author":"Kansara","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_91","first-page":"1200","article-title":"Suprachoroidally Delivered DNA Nanoparticles Produce Human Myosin7A Protein in RPE-Choroid in Rabbits","volume":"62","author":"Kansara","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1136\/jmg.2006.045377","article-title":"MYO7A Mutation Screening in Usher Syndrome Type I Patients from Diverse Origins","volume":"44","author":"Jaijo","year":"2007","journal-title":"J. Med. Genet."},{"key":"ref_93","first-page":"233","article-title":"Hydrostatic Pressure of the Suprachoroidal Space","volume":"30","author":"Emi","year":"1989","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_94","first-page":"5259","article-title":"Intraocular Distribution and Targeting of Triamcinolone Acetonide Suspension Administered Into the Suprachoroidal Space","volume":"55","author":"Edelhauser","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_95","first-page":"3977","article-title":"Suprachoroidal CLS-AX (Axitinib Injectable Suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)","volume":"61","author":"Kaiser","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and Closure Kinetics of the Suprachoroidal Space Following Microneedle Injection of Liquid Formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_97","first-page":"320","article-title":"Distribution of Aqueous Solutions Injected Suprachoroidally (SC) in Rabbits","volume":"61","author":"Nork","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1167\/iovs.15-16597","article-title":"Real-Time Monitoring of Suprachoroidal Space (SCS) Following SCS Injection Using Ultra-High Resolution Optical Coherence Tomography in Guinea Pig Eyes","volume":"56","author":"Gu","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance Kinetics and Clearance Routes of Molecules From the Suprachoroidal Space After Microneedle Injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejpb.2015.05.020","article-title":"Formulation to Target Delivery to the Ciliary Body and Choroid via the Suprachoroidal Space of the Eye Using Microneedles","volume":"95","author":"Kim","year":"2015","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exer.2016.10.011","article-title":"Distribution of Particles, Small Molecules and Polymeric Formulation Excipients in the Suprachoroidal Space after Microneedle Injection","volume":"153","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1167\/iovs.16-21230","article-title":"A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs","volume":"58","author":"Tran","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/09205063.2012.745714","article-title":"Evaluation of RGD Peptide Hydrogel in the Posterior Segment of the Rabbit Eye","volume":"24","author":"Wang","year":"2013","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/IAE.0b013e3182576d1d","article-title":"Pharmacokinetic Comparison of Ketorolac after Intracameral, Intravitreal, and Suprachoroidal Administration in Rabbits","volume":"32","author":"Wang","year":"2012","journal-title":"Retina"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/09273948.2021.1954199","article-title":"Suprachoroidal CLS-TA with and without Systemic Corticosteroid and\/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial","volume":"31","author":"Merrill","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2023.2262015","article-title":"Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial","volume":"2","author":"Shah","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_107","first-page":"3561","article-title":"Efficacy of Suprachoroidal Triamcinolone Acetonide for Uveitic Cystoid Macular Edema","volume":"64","author":"Zhou","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40123-022-00603-x","article-title":"Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies","volume":"12","author":"Yeh","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.9.11.27","article-title":"Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders","volume":"9","author":"Wan","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Fazel, F., Malekahmadi, M., Feizi, A., Oliya, B., Tavakoli, M., and Fazel, M. (2023). Suprachoroidal Injection of Triamcinolone Acetonide plus Intravitreal Bevacizumab in Diabetic Macular Edema: A Randomized Pilot Trial. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-02790-y"},{"key":"ref_111","unstructured":"Oxular Limited (2023, December 31). Oxulumis\u00ae Suprachoroidal Microcatherization of Triesence\u00ae in Diabetic Macular Edema (CAPE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05512962."},{"key":"ref_112","first-page":"2233","article-title":"Suprachoroidal Administration of Aflibercept Protects against Neovascularization in the Mouse CNV Model","volume":"64","author":"Jokinen","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_113","unstructured":"Oxular Limited (2023, December 31). Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex\u00ae in the Treatment of Diabetic Macular Edema (OXEYE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05697809."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40942-023-00458-9","article-title":"Visual Function and Retinal Morphological Changes after Single Suprachoroidal Delivery of Fluocinolone Acetonide (Iluvien\u00ae) Implant in Eyes with Chronic Diabetic Macular Edema","volume":"9","author":"Leila","year":"2023","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_115","first-page":"2611","article-title":"Suprachoroidal Delivery of CLS-301, a Potent Small Molecule Integrin Antagonist, Offers Multimonth Durability and High Bioavailability in the Chorioretina","volume":"64","author":"Kansara","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_116","first-page":"2194","article-title":"Long-Acting Potential of Suprachoroidally Delivered BCX4161, a Selective Plasma Kallikrein Inhibitor, for Diabetic Macular Edema","volume":"62","author":"Muya","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Ali, B.M., Azmeh, A.M., and Alhalabi, N.M. (2023). Suprachoroidal Triamcinolone Acetonide for the Treatment of Macular Edema Associated with Retinal Vein Occlusion: A Pilot Study. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-02808-5"},{"key":"ref_118","first-page":"45","article-title":"Effect of Supra-Choroidal Triamcinolone Injection on Best-Corrected Visual Acuity and Central Retinal Thickness in Patients with Macular Edema Secondary to Retinal Vein Occlusion","volume":"38","author":"Muslim","year":"2022","journal-title":"Pak. J. Ophthalmol."},{"key":"ref_119","unstructured":"Clearside Biomedical (2023, December 31). Extension Study to Evaluate the Long-Term Outcomes of Subjects Following CLS-AX Administration for Age-Related Macular Degeneration in the CLS-AX CLS1002-101 Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05131646."},{"key":"ref_120","unstructured":"Clearside Biomedical (2023, December 31). Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (ODYSSEY), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05891548."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"eadl3576","DOI":"10.1126\/sciadv.adl3576","article-title":"Suprachoroidal Gene Transfer with Nonviral Nanoparticles in Large Animal Eyes","volume":"10","author":"Shen","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_122","unstructured":"Aura Biosciences (2023, December 31). A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06007690."},{"key":"ref_123","unstructured":"(2024, May 27). Aura Biosciences Presents Final Phase 1b\/2 Data for Its First Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting\u2014Aura Biosciences. Available online: https:\/\/ir.aurabiosciences.com\/news-releases\/news-release-details\/aura-biosciences-presents-final-phase-1b2-data-its-first-virus\/."},{"key":"ref_124","unstructured":"Aura Biosciences (2023, December 31). Study in Subjects with Small Primary Choroidal Melanoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03052127."},{"key":"ref_125","unstructured":"Aura Biosciences (2024, March 17). A Prospective Group-Matched Study of Visual Outcomes in Subjects Treated with Belzupacap Sarotalocan (AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL\/CM), Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OPTH.S180580","article-title":"Macular Edema Associated with Non-Infectious Uveitis: Pathophysiology, Etiology, Prevalence, Impact and Management Challenges","volume":"13","author":"Massa","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ajo.2008.09.014","article-title":"Incidence and Prevalence of Uveitis in Veterans Affairs Medical Centers of the Pacific Northwest","volume":"146","author":"Suhler","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/DDDT.S166092","article-title":"Update in Treatment of Uveitic Macular Edema","volume":"13","author":"Koronis","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"PEACHTREE Study Investigators Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_130","first-page":"3206","article-title":"Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Uveitis: Visual and Anatomic Outcomes by Age","volume":"63","author":"Henry","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_131","first-page":"1139","article-title":"Extension Study of the Safety and Efficacy of CLS-TA for Treatment of Macular Oedema Associated with Non-Infectious Uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","article-title":"Suprachoroidal CLS-TA for Non-Infectious Uveitis: An Open-Label, Safety Trial (AZALEA)","volume":"106","author":"Henry","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_134","unstructured":"American Academy of Ophthalmology (2024, May 28). Diabetic Macular Edema: Diagnosis and Management. Available online: https:\/\/www.aao.org\/eyenet\/article\/diabetic-macular-edema-diagnosis-and-management."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients with Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/IAE.0000000000002302","article-title":"Changes In Diabetic Retinopathy Severity When Treating Diabetic Macular Edema with Ranibizumab: DRCR.Net Protocol I 5-Year Report","volume":"38","author":"Bressler","year":"2018","journal-title":"Retina"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"HULK Study Group Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol. Retin."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oret.2020.08.007","article-title":"Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study","volume":"5","author":"Barakat","year":"2021","journal-title":"Ophthalmol. Retin."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"304","DOI":"10.53350\/pjmhs22166304","article-title":"Comparison of Suprachoroidal Injection of Triamcinolone Acetonide Versus Intravitreal Bevacizumab in Primary Diabetic Macular Odema","volume":"16","author":"Anwar","year":"2022","journal-title":"Pak. J. Med. Health Sci."},{"key":"ref_140","unstructured":"Oxular Limited (2024, May 30). Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema. Available online: https:\/\/www.biospace.com\/article\/oxular-doses-first-patients-in-oxeye-phase-2-clinical-trial-of-suprachoroidal-oxu-001-as-a-long-acting-treatment-for-diabetic-macular-edema\/."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-Term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","article-title":"Three-Year Safety and Efficacy of the 0.19-Mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study","volume":"129","author":"Singer","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000455235","article-title":"A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN\u00ae in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND)","volume":"57","author":"Figueira","year":"2017","journal-title":"Ophthalmic. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/13543784.2020.1795639","article-title":"Anti-Integrin Therapy for Retinovascular Diseases","volume":"29","author":"Bhatwadekar","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_145","first-page":"3010","article-title":"Increased Expression of Integrin \u03b1 Chains and Their Ligands during Laser-Induced Neovascularization of Rat Choroid","volume":"53","author":"Nakajima","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2337\/db10-1260","article-title":"Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats","volume":"60","author":"Clermont","year":"2011","journal-title":"Diabetes"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/tjo.tjo_9_17","article-title":"Management of Macular Edema Due to Central Retinal Vein Occlusion\u2014The Role of Aflibercept","volume":"7","author":"Rhoades","year":"2017","journal-title":"Taiwan J. Ophthalmol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Tanzanite Study Group Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol. Retin."},{"key":"ref_149","unstructured":"Clearside Biomedical (2023, December 31). Suprachoroidal Injection of Triamcinolone Acetonide with IVT Anti-VEGF in Subjects with Macular Edema Following RVO (TOPAZ), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03203447."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/OPTH.S361636","article-title":"Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients","volume":"16","author":"Nawar","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","article-title":"The Prevalence of Age-Related Macular Degeneration in Asians: A Systematic Review and Meta-Analysis","volume":"117","author":"Kawasaki","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_152","first-page":"S2","article-title":"Geographic Atrophy: Mechanism of Disease, Pathophysiology, and Role of the Complement System","volume":"29","author":"Bakri","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the Management of Neovascular Age-Related Macular Degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Chong","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Fujioka, J.K., Gholamian, T., Zaharia, M., and Tran, S.D. (2023). Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091241"},{"key":"ref_155","first-page":"459","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina","volume":"38","author":"Muya","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"ref_156","unstructured":"Clearside Biomedical (2024, May 28). Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (Axitinib Injectable Suspension) in Wet AMD|Clearside Biomedical, Inc.\u2014IR Site. Available online: https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-plans-odyssey-phase-2b-clinical."},{"key":"ref_157","unstructured":"Clearside Biomedical (2023, December 31). Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD (OASIS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04626128."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal Melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3892\/etm.2021.10863","article-title":"Uveal Melanoma Diagnosis and Current Treatment Options (Review)","volume":"22","author":"Branisteanu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.6004\/jnccn.2018.0042","article-title":"New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma","volume":"16","author":"Barker","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3857\/roj.2020.00318","article-title":"Clinical Management of Uveal Melanoma: A Comprehensive Review with a Treatment Algorithm","volume":"38","author":"Sayan","year":"2020","journal-title":"Radiat. Oncol. J."},{"key":"ref_162","first-page":"3615","article-title":"Ocular Distribution and Efficacy after Suprachoroidal Injection of AU-011 for Treatment of Ocular Melanoma","volume":"61","author":"Savinainen","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_163","first-page":"1459","article-title":"Suprachoroidal Injection of Microspheres with Microcatheter in a Rabbit Model of Uveal Melanoma","volume":"52","author":"Kang","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"S924","DOI":"10.1016\/j.annonc.2022.07.968","article-title":"A Phase II Trial of AU-011, an Investigational, Virus-like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL\/CM) Using Suprachoroidal Administration","volume":"33","author":"Demirci","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Demirci, H., Narvekar, A., Murray, C.C., and Rich, C.C. (2022). A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), An Investigational, Virus-like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL\/CM) Using Suprachoroidal Administration\u2014(NCT04417530), Elsevier.","DOI":"10.1016\/j.annonc.2022.07.968"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/IJG.0b013e31814b990d","article-title":"Barriers to Glaucoma Drug Delivery","volume":"17","author":"Ghate","year":"2008","journal-title":"J. Glaucoma"},{"key":"ref_167","first-page":"536","article-title":"Experimental Ciliochoroidal Detachment. Effect on Intraocular Pressure and Aqueous Humor Flow","volume":"97","author":"Pederson","year":"1979","journal-title":"Arch. Ophthalmol. 1960"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Hao, H., He, B., Yu, B., Yang, J., Xing, X., and Liu, W. (2022). Suprachoroidal Injection of Polyzwitterion Hydrogel for Treating Glaucoma. Biomater. Adv., 142.","DOI":"10.1016\/j.bioadv.2022.213162"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2001908","DOI":"10.1002\/advs.202001908","article-title":"Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel","volume":"8","author":"Chae","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained Reduction of Intraocular Pressure by Supraciliary Delivery of Brimonidine-Loaded Poly(Lactic Acid) Microspheres for the Treatment of Glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_171","unstructured":"Priyan, V. (2021). Arctic Vision Starts Dosing with ARVN001 in Macular Oedema Trial. Clin. Trials Arena."},{"key":"ref_172","unstructured":"(2024, July 07). Arctic Vision Arctic Vision Announces First Patient Dosed in Phase 1 Clinical Trial of ARVN001 for the Treatment of Diabetic Macular Edema (DME) in China. Available online: https:\/\/www.arcticvision.com\/newsdetail\/id\/57.html."},{"key":"ref_173","first-page":"4954","article-title":"Post Hoc Analysis of Clinical Suprachoroidal Injection Experience across Indications","volume":"61","author":"Barakat","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/1007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:53Z","timestamp":1760110013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":173,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ph17081007"],"URL":"https:\/\/doi.org\/10.3390\/ph17081007","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}